September 30, 2012Open Access

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Key Points

Key points are not available for this paper at this time.

Abstract

Dabrafenib and trametinib were safely combined at full monotherapy doses. The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced. Progression-free survival was significantly improved. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01072175.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Flaherty et al. (Sun,) studied this question.

www.synapsesocial.com/papers/69d8cbaa270e68ba94bed8db — DOI: https://doi.org/10.1056/nejmoa1210093

Authors

Keith T. Flaherty

J. Infante

Adil Daud

Journals

New England Journal of Medicine

Actions

Institutions

University of Pennsylvania

University of California, San Francisco

Massachusetts General Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion